# Isomorphic Labs Adds Merck as AI Drug Discovery Partner Days After $5 Billion Raise

Isomorphic Labs has signed a partnership with Merck & Co., the company announced days after raising $5 billion. The deal brings Merck into an existing roster of collaborators that now includes three of the four largest drugmakers by revenue.

The AI-powered biotech firm did not disclose financial terms of the Merck agreement. The partnership is focused on using Isomorphic’s artificial intelligence platform to discover and design new drugs. Isomorphic, a London-based company spun out of Alphabet’s DeepMind, applies machine learning to protein structure prediction and molecular design.

The new deal comes on the heels of a $5 billion financing round, the largest ever for a private AI drug discovery company. That raise, and the string of partnerships, signal rapid momentum for the field.

**Why this matters in life sciences**

AI-driven drug discovery aims to shorten the years-long process of identifying viable drug candidates. By predicting how molecules will interact with biological targets, platforms like Isomorphic’s can reduce the need for expensive, trial-and-error lab work. Large pharmaceutical companies are increasingly turning to such tools to improve R&D productivity. The involvement of Merck, alongside other top drugmakers, suggests that major pharma views AI as a core part of future drug development rather than an experimental sideline. This trend could accelerate the pace of new therapies reaching patients across oncology, neurology, and other therapeutic areas.

Source: [original report](https://www.fiercebiotech.com/biotech/isomorphic-labs-adds-merck-ai-drug-discovery-roster-days-after-5b-raise)